Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 1,307 trials

Esketamine for Schizophrenia Symptoms

We are studying whether esketamine can reduce depressive and negative symptoms in people with schizophrenia. The trial also looks at whether it causes any worsening of psychotic symptoms.

Negative and Depressive Symptoms in Schizophrenia and Schizoaffective Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Flecainide vs. Amiodarone

We are studying whether flecainide is more effective and safe than amiodarone for treating paroxysmal atrial fibrillation in patients with coronary disease. This trial aims to see if it can restore normal heart rhythm faster and reduce hospital visits.

Coronary Artery DiseaseParoxysmal Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Refractory Schizophrenia: NaBen® with Clozapine

We are studying whether NaBen®, a new medication, can help adults with refractory schizophrenia who still have symptoms despite treatment with clozapine. The trial will also assess the safety of this combination therapy.

Treatment-resistant Schizophrenia≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementPsychiatry

Crohn's Disease in Children: Budesonide Treatment

We are studying a topical treatment with budesonide for children with Crohn's disease affecting the esophagus, stomach, or duodenum. The goal is to see if it helps reduce inflammation in these areas.

Crohn's Disease≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyPediatrics

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Chronic HDV Infection: Tobevibart and Elebsiran Study

We are studying a new combination therapy for people with chronic HDV infection who haven't responded to prior treatment. The goal is to see if this therapy can effectively reduce the virus and improve liver health.

Chronic Hepatitis D Virus Infection>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious Diseases

Metastatic Colorectal Cancer: Cetuximab vs. Bevacizumab

We are studying whether continuing cetuximab treatment helps patients with specific types of metastatic colorectal cancer after their first treatment stops working. This trial compares it to another treatment option to see which is more effective.

Metastatic Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Endometrial Cancer: Sacituzumab Tirumotecan and Pembrolizumab Study

We are studying a combination of sacituzumab tirumotecan and pembrolizumab for people with advanced or recurrent endometrial cancer. The goal is to see if this combination works better than pembrolizumab alone.

Endometrial CarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncology

Low-Grade Upper Tract Urothelial Cancer: UGN-104 Treatment Study

We are studying a new treatment called UGN-104 for patients with low-grade upper tract urothelial cancer. The trial aims to see how well it reduces tumors and its safety compared to existing options.

Low-grade Upper Tract Urothelial Cancer1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Dry Eye Disease: PRGF Eye Drops for Glaucoma Patients

We are studying whether PRGF eye drops can help relieve dry eye symptoms in patients with glaucoma. The trial also looks at the safety of these eye drops for this condition.

GlaucomaDry Eye Disease≤3 monthsConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesOphthalmology

Bowel Dysfunction After Rectal Cancer Surgery: Irrigation vs. Suppositories

We are comparing transanal irrigation and glycerol suppositories to see which treatment better improves bowel function and quality of life for patients after rectal cancer surgery.

Low Anterior Resection Syndrome≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Choline Chloride for Injection in Intestinal Failure

We are studying the safety and effectiveness of Choline Chloride for Injection in adolescents and adults with intestinal failure. This trial compares the treatment to a placebo to see how well it supports patients receiving long-term parenteral nutrition.

Intestinal Failure1-2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyNephrology

Meningococcal Vaccine Study for Ages 10-20

We are testing a booster dose of the rMenB+OMV NZ vaccine in healthy participants aged 10 to 20 who were vaccinated in early childhood. The study aims to see how well it enhances their immune response and evaluates its safety.

Invasive Meningococcal DiseaseConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Solid Tumors: MK-5684 Study

We are testing a new treatment, MK-5684, for people with certain solid tumors to see if it helps them live longer without disease progression. The study also evaluates its safety and effectiveness compared to standard care.

Breast CancerOvarian CancerEndometrial Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Chronic Heart Failure: Combined Diuretic Therapy Study

We are comparing a new combined diuretic treatment to standard therapies for people with chronic heart failure. The goal is to see if it improves exercise capacity and fluid management.

Congestive Heart Failure>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Melanoma Treatment: Comparing Immune Therapies

We are studying two different immune therapy treatments for patients with resectable stage III melanoma. Our goal is to see which treatment may help improve survival without disease progression.

Stage III Malignant MelanomaConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology